Grant: CAG/CIHR Fellowship for Research in Gastroenterology/Nutrition
University of Toronto
$120,000.00
Studies on the effect of feeding anti-CD3 Antibody in the prevention and treatment of colitis
FY 2008-09
Summary
Over 200,000 Canadians suffer from inflammatory bowel diseases (IBD) such as Crohn¿s disease (CD) or ulcerative colitis (UC). To date there are no known treatments to cure the disease. Although the cause of IBD is unknown, the theory is that IBD has a genetic basis that leads to abnormal interactions between the immune system and environmental agents or triggers. To find a cure we need to understand the basic principles that govern the function of the gut¿s immune system. The immune system of the gut protects against harmful agents while at the same time controls excessive or inappropriate responses against ¿normal¿ bacteria and food related antigens. Indeed, feeding substances leads to "oral tolerance", where immune response to that substance is minimized. This fine balance is lost in patients with IBD. Studies in humans and animals suggest that T cells are involved in both the induction and regulation of inflammatory processes in IBD. T cells distinguish foreign from self via the T cell receptor (TCR). A subset of T cells called regulatory T cells (Treg) are key to preventing self-reactivity as well as preventing excessive T cell responses. We hypothesize that IBD can be treated by activation of regulatory T cells. We will explore a novel way to induce Treg cells in a mouse model of colitis. We will feed mice with an antibody specific for the TCR (anti-CD3 mAb). This treatment was previously shown to be effective in mouse models of other autoimmune disease. We expect to induce oral tolerance and/or down regulate inappropriate immune responses against normal gut bacteria by induction of Treg. If feeding of CD3-MAb suppresses T cell mediated colitis this could open up new strategies for therapy in patients with IBD. Indeed the commercial availability of anti-human CD3-Mab, OKT3 currently in use in preventing transplant rejection in humans allows one to consider evaluating the efficacy of feeding this biological as a new treatment of IBD patients.
Department
Program
CAG/CIHR Fellowship for Research in Gastroenterology/Nutrition
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
175661
Name
Forster Katharina
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Partnername
Canadian Association of Gastroenterology (Oakville, Ontario)
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
CIHR - INMD - CAG (Canadian Association of Gastroenterology) Partnership
Projecttitle
Studies on the effect of feeding anti-CD3 Antibody in the prevention and treatment of colitis
Programtype2
Fellowship Programs
Orgnameinp2
University of Toronto
Cihramount2
$120,000
Cihrequipment2
$0
Programname2
CAG/CIHR Fellowship for Research in Gastroenterology/Nutrition
Keyworddelim
Animal Models; Ibd; Musosal Immunology; Musosal Inflammation; Oral Tolerance; Regulatory Tcell; T Cell
Abstract
Over 200,000 Canadians suffer from inflammatory bowel diseases (IBD) such as Crohn¿s disease (CD) or ulcerative colitis (UC). To date there are no known treatments to cure the disease. Although the cause of IBD is unknown, the theory is that IBD has a genetic basis that leads to abnormal interactions between the immune system and environmental agents or triggers. To find a cure we need to understand the basic principles that govern the function of the gut¿s immune system. The immune system of the gut protects against harmful agents while at the same time controls excessive or inappropriate responses against ¿normal¿ bacteria and food related antigens. Indeed, feeding substances leads to "oral tolerance", where immune response to that substance is minimized. This fine balance is lost in patients with IBD. Studies in humans and animals suggest that T cells are involved in both the induction and regulation of inflammatory processes in IBD. T cells distinguish foreign from self via the T cell receptor (TCR). A subset of T cells called regulatory T cells (Treg) are key to preventing self-reactivity as well as preventing excessive T cell responses. We hypothesize that IBD can be treated by activation of regulatory T cells. We will explore a novel way to induce Treg cells in a mouse model of colitis. We will feed mice with an antibody specific for the TCR (anti-CD3 mAb). This treatment was previously shown to be effective in mouse models of other autoimmune disease. We expect to induce oral tolerance and/or down regulate inappropriate immune responses against normal gut bacteria by induction of Treg. If feeding of CD3-MAb suppresses T cell mediated colitis this could open up new strategies for therapy in patients with IBD. Indeed the commercial availability of anti-human CD3-Mab, OKT3 currently in use in preventing transplant rejection in humans allows one to consider evaluating the efficacy of feeding this biological as a new treatment of IBD patients.
Competitiondate
200810
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Forster, Katharina
Approvedterm
2 ans 0 mois
Cihrcontribution2
Inst of Nutr Metabolism &Diab~ $120,000~ $0~